Androlog Mail
The following are related to the use of androgens or anabolic-androgenic
steroids, prescription & illicit, and inquiries put forth to formulate
options or methodologies in the study of androgen induced hypogonadism.
Thank you for your attention and time.
Would there be a benefit to a medical protocol for HPGA normalization in
androgen induced hypogonadism compared with no treatment?
Regarding only androgen induced hypogonadism to what extent has HPGA
normalization been studied?
Theoretically, if found to be effective are there any major risks in
treating hypogonadism with short-term, less than 30-60 days, of tamoxifen?
(Tamoxifen has been associated with in increased pulmonary emboli (DVT/PE)
in a study of breast cancer patients.)
Is there a conventional medical management for the hypogonadism of black-
market, illicit, or prescription AAS or androgen users?
Would a model of AAS or androgen abuse, dependency or addiction be
interrelated to the type, dose and duration of androgen(s) used?
Should a model for AAS or androgen abuse, dependency or addiction take into
consideration the signs and symptoms of hypogonadism?
Would a medical protocol not involving the use of AAS or androgens to
correct androgen induced hypogonadism be of clinical benefit?
Would abuse, dependency or addiction be better assessed in individuals after
the correction of hypogonadism if a medical protocol was available?
Michael C Scally, M.D.
713-461-0897
fax. 713-461-1097
Email. mscally@alum.mit.edu
Peace
This archive was generated by hypermail 2.1.2 : Fri Nov 22 2002 - 08:18:39 CST